Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicinal composition for prevention or treatment of parasitic protozoan infection

A technology for protozoa and infectious diseases, which is used in drug combinations, anti-infective drugs, medical preparations containing active ingredients, etc.

Active Publication Date: 2007-09-05
FUJIFILM CORP +1
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

), but little is known about the causal relationship between parasitic infections and the effects of drugs, and in this situation, it is extremely difficult to discover the structure of compounds that are effective against protozoan infections

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition for prevention or treatment of parasitic protozoan infection
  • Medicinal composition for prevention or treatment of parasitic protozoan infection
  • Medicinal composition for prevention or treatment of parasitic protozoan infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0063] 1-1. Cultivation of Drug-Susceptible Tropical Fever Malaria Protozoa

[0064] In this example, a protozoan of Plasmodium falciparum F CR-3 strain was used. The medium used in the experiment was filter-sterilized RPMI-1640 medium, the pH of which was adjusted to 7.4, and human serum was added to a final concentration of 10%. The cultivation of malaria protozoa in O 2 Concentration 5%, CO 2 Concentration 5%, N 2 The concentration is 90%, and the temperature is 36.5°C.

[0065] 1-2. Drug-sensitive Tropical Fever Malaria Protozoan Proliferation Inhibition Screening Test

[0066] The cultured malarial protozoa-infected erythrocytes were collected by centrifugation, washed with serum-containing medium, and then non-infected erythrocytes were added. The initial infection rate was 0.3%. The hematocrit value at this time was 3%. The compound of the present invention used in the test and the positive drug (chloroquine, quinine) were dissolved in dimethyl sulfoxide (DMSO) as...

Embodiment 2

[0086] 2-1. Cultivation of chloroquine-resistant tropical malaria protozoa

[0087] A protozoa of Plasmodium falciparum K1 strain was used in this example. The culture medium used in the experiment is a culture medium formed by adding human serum at a final concentration of 5% to the filter-sterilized RPMI-1640 medium. The cultivation of malaria protozoa in O 2 Concentration 3%, CO 2 Concentration 4%, N 2 The concentration was 93%, and the temperature was 37°C.

[0088] 2-2. Chloroquine-resistant Tropical Fever Malaria Protozoan Proliferation Inhibition Screening Test

[0089] The compound of the present invention used in the test-positive object drug (chloroquine) was dissolved in DMSO to prepare a test solution with a predetermined concentration. The cultured malarial protozoa-infected erythrocytes were collected by centrifugation and diluted with non-infected erythrocytes. The initial infection rate was 0.15%. The hematocrit value at this time was 2.5%. Add 200 μL of...

Embodiment 3

[0109] 3-1. Culture of African trypanosomiasis protozoa

[0110] In this example, the bloodstream-dwelling trypanomastigotes of the protozoa of Trypanosoma brucei rhodensiense (STIB900 strain) were used. The medium used in the experiment was filter-sterilized MEM medium supplemented with 25mM N-2-hydroxyethylpiperazine-2-ethanesulfonic acid (HEPES), 1g / L glucose, 1% MEM non- Essential amino acids, 0.2 mM 2-mercaptoethanol, 2 mM sodium pyruvate, 0.1 mM hypoxanthine, and 15% heat-treated horse serum. Protozoa were cultured in CO 2 Concentration of 5% in the air, at a temperature of 37 degrees.

[0111] 3-2. African trypanosomiasis protozoan proliferation inhibition screening test

[0112] The compound of the present invention used in the test and the positive drug (Melarsoprol (Melarsoprol)) were dissolved in dimethyl sulfoxide (DMSO) to prepare a test solution with a predetermined concentration. In the wells of the 96-well culture plate, the number of protozoa containing 8×...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A medicinal composition for the prevention or treatment of parasitic protozoan infection which has highly selective toxicity to parasitic protozoan infection and produces a high preventive or therapeutic effect thereon. The medicinal composition for the prevention or treatment of parasitic protozoan infection is characterized by containing a compound represented by the following general formula (1) as an active ingredient. [Chemical formula 1] (In the formula, R represents alkyl, aryl, or a heterocyclic group; A and B each independently represents a 5- or 6-membered ring containing at least one heteroatom or a fused ring comprising the 5- or 6-membered ring and one or more 3- to 8-membered rings fused therewith; Y represents S, O, Se, or -NR<1>- (R<1> represents alkyl, aryl or a heterocyclic group); L<1>, L<2>, L<3>, L<4>, and L<5> each independently represents methine; Q represents a physiologically acceptable anion; k is an integer of 0-2 which is necessary for making the charge of the whole molecule zero; and p and q each is 0-3, provided that p+q is an integer of 1-6.

Description

technical field [0001] The present invention relates to a pharmaceutical composition useful for the prevention or treatment of parasitic protozoan infectious diseases. Background technique [0002] Known so far, especially in areas centered on tropical and subtropical regions, there are many parasitic protozoan infectious diseases, for example, malaria, leishmaniasis, African trypanosomiasis (African sleeping sickness), American cone Worm disease (Chagas (Chagas)), lymphatic filariasis, babesiosis, etc. Among them, infectious diseases can be divided into infectious diseases that only infect humans, and zoonotic infectious diseases that also infect domestic animals and small animals. No matter which infectious disease causes serious economic and social damage. Currently, in these diseases, there are problems such as the absence of drugs with sufficient therapeutic effects, the emergence and spread of protozoa resistant to therapeutic drugs, and side effects of therapeutic dr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/428A61K31/427A61P33/02A61P33/06C07D277/64C07D277/84C07D417/14A61K31/4439A61K31/4709
CPCC07D277/84A61K31/427A61K31/428A61K31/4439A61K31/4709C07D277/64C07D417/14A61P33/02A61P33/06Y02A50/30
Inventor 井原正隆高须清诚普多霍姆·卡尼塔北口博司川上雅之佐藤幸藏
Owner FUJIFILM CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com